

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 1 | 1 | — | — | — | 1 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | 1 | — | — | — | 1 |
| Drug common name | Bempegaldesleukin |
| INN | bempegaldesleukin |
| Description | Bempegaldesleukin (development code NKTR-214) is an experimental anti-cancer drug candidate. It is a PEGylated interleukin-2 (IL-2) acting as a CD122-preferential IL-2 pathway agonist designed to activate and proliferate CD8+ T cells and NK cells. It is being developed by Nektar Therapeutics.
|
| Classification | Protein |
| Drug class | interleukins: interleukin-2 analogues and derivatives; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | — |
| PDB | — |
| CAS-ID | 1939126-74-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298058 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15140 |
| UNII ID | BNO1JG5MZC (ChemIDplus, GSRS) |

